Abstract
Introduction Recent debates surrounding the lagging covid-19 vaccination campaigns in low-income countries center around vaccine supply and financing. Yet, relatively little is known about attitudes towards covid-19 vaccines in these countries and in Africa in particular. In this paper, we provide cross-country comparable estimates of the willingness to accept a covid-19 vaccine in six Sub-Saharan African countries.
Methods We use data from six national high-frequency phone surveys from countries representing 38% of the Sub-Saharan African population (Burkina Faso, Ethiopia, Malawi, Mali, Nigeria, and Uganda). Samples are drawn from large, nationally representative sampling frames providing a rich set of demographic and socio-economic characteristics by which we disaggregate our analysis. Using a set of re-calibrated survey weights, our analysis adjusts for the selection biases common in remote surveys.
Results Acceptance rates in the six Sub-Saharan African countries studied are generally high, with at least four in five people willing to be vaccinated in all but one country. Vaccine acceptance ranges from nearly universal in Ethiopia (97.9%, 97.2% to 98.6%) to below what would likely be required for herd immunity in Mali (64.5%, 61.3% to 67.8%). We find little evidence for systematic differences in vaccine hesitancy by sex or age but some clusters of hesitancy in urban areas, among the better educated, and in richer households. Safety concerns about the vaccine in general and its side effects emerge as the primary reservations toward a covid-19 vaccine across countries.
Conclusions Our findings suggest that limited supply, not inadequate demand, likely presents the key bottleneck to reaching high covid-19 vaccine coverage in Sub-Saharan Africa. To turn intent into effective demand, targeted communication campaigns bolstering confidence in the safety of approved vaccines and reducing concerns about side effects will be crucial to safeguard the swift progression of vaccine rollout in one of the world’s poorest regions.
What is already known?
What is already known?
Estimates of vaccine acceptance in high- and middle-income countries have found rates to cluster around 70% with considerable cross-country variation.
As vaccine rollout is severely lagging, low-income countries and particularly Sub-Saharan Africa (SSA) with almost two thirds of the global poor population remain exposed to covid-19 and its impacts on lives and livelihoods.
Much of the current debate on vaccination campaigns in SSA focuses on supply-chain and financial factors, yet there is a dearth of robust, comparable evidence on covid-19 vaccine hesitancy in these countries.
What are the key findings?
What are the key findings?
Covid-19 vaccine acceptance is high in six Sub-Saharan African countries with an estimated four in five people or more in all but one study country willing to take an approved, free vaccine.
Clusters of hesitancy vary by country but generally comprise urban areas, richer households, and those with more education.
What do the new findings imply?
What do the new findings imply?
Limited supply, rather than inadequate demand, likely presents the key bottleneck to achieving high covid-19 vaccine coverage in Sub-Saharan Africa.
To reach mass coverage, information campaigns should bolster confidence in vaccine safety and alleviate concerns about side effects.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the analysis comes from the World Bank Multi-Donor Trust Fund for Integrated Household and Agricultural Surveys in Low and Middle-Income Countries (TF072496). The funders had no role in study design, data collection, analysis, interpretation of the data, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data for our study were openly available before the initiation of the study and can be accessed under the links provided in the data availability statement.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are available from the World Bank's Microdata Library, High Frequency Phone Survey Catalog https://microdata.worldbank.org/index.php/catalog/hfps) as well as LSMS catalog (https://microdata.worldbank.org/index.php/catalog/lsms).
